Patents Assigned to TG BIOTECH
  • Method for preparing extract with increasing damulin A and damulin B contents, and pharmaceutical compositions of the same for treating metabolic disease
    Patent number: 8357786
    Abstract: Disclosed is an AMPK activating material used for improving and treating metabolic syndrome, in which AMPK (AMP-activated protein kinase) is a main enzyme for regulating an energy sensor and lipid/glucose metabolism in the body. The activation of AMPK inhibits the synthesis of fat and cholesterol, and accelerates the reduction of body fat and blood glucose, thereby improving obesity, diabetes, and hyperlipidaemia. The disclosed AMPK activating material contains, as active ingredients having an improving and treating effect on metabolic syndrome, including obesity, diabetes, and hyperlipidaemia, a novel compound 2?,3?,12?-trihydroxydammar-20(22)-E,24-diene-3-O-[?-D-glucopyranosyl-(1?)-?-D-glucopyranoside], named Damulin A, and a novel compound 2?,3?,12?-trihydroxydammara-20,24-diene-3-O-[?-D-glucopyranosyl-(1?)-?-D-glucopyranoside], named Damulin B.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: January 22, 2013
    Assignee: TG Biotech Co., Ltd.
    Inventors: Tae Lin Huh, He Bok Song, Ji Eun Kim, So Young Joon, Won Keun Oh
  • METHOD FOR PREPARING GYNOSTEMMA PENTAPHYLLUM EXTRACT WITH INCREASING DAMULIN A AND DAMULIN B CONTENTS, AND PHARMACEUTICAL COMPOSITIONS OF THE SAME FOR TREATING METABOLIC DISEASE
    Publication number: 20110015142
    Abstract: Disclosed is an AMPK activating material used for improving and treating metabolic syndrome, in which AMPK (AMP-activated protein kinase) is a main enzyme for regulating an energy sensor and lipid/glucose metabolism in the body. The activation of AMPK inhibits the synthesis of fat and cholesterol, and accelerates the reduction of body fat and blood glucose, thereby improving obesity, diabetes, and hyperlipidaemia. The disclosed AMPK activating material contains, as active ingredients having an improving and treating effect on metabolic syndrome, including obesity, diabetes, and hyperlipidaemia, a novel compound 2?,3?,12?-trihydroxydammar-20(22)-E,24-diene-3-O-[?-D-glucopyranosyl-(1?)-?-D-glucopyranoside], named Damulin A, and a novel compound 2?,3?,12?-trihydroxydammara-20,24-diene-3-O-[?-D-glucopyranosyl-(1?)-?-D-glucopyranoside], named Damulin B.
    Type: Application
    Filed: January 29, 2010
    Publication date: January 20, 2011
    Applicant: TG BIOTECH CO. LTD.
    Inventors: Tae Lin HUH, He Bok SONG, Ji Eun KIM, So Young JOON, Won Keun OH
  • COMPOSITION FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME CONTAINING OBOVATOL AND ITS SYNTHESIZED DERIVATIVES
    Publication number: 20100125103
    Abstract: Disclosed is a pharmaceutical composition containing obovatol represented by Formula 1 and its derivatives. The obovatol and its derivatives effectively increase the activity of AMPK (AMP-activated protein kinase) that plays an important role in diabetes and metabolic syndrome, and thus may be variously used in treating diabetes and metabolic syndrome. (In Formula 1, R1, R2 and R3 are the same as defined above).
    Type: Application
    Filed: June 15, 2009
    Publication date: May 20, 2010
    Applicants: TG BIOTECH CO. LTD., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Tae-Lin Huh, Hebok Song, Ji-Eun Kim, Byoung-Mog Kwon, Dong Cho Han, Hye-Nan Kim
  • TREATMENT OF INSULIN RESISTANCE SYNDROME
    Publication number: 20060246163
    Abstract: The present application describes a composition that includes an extract of Gynostemma pentaphyllum used to treat insulin resistance syndrome, obesity, hypertriglyceridemia, as well as decrease body fat mass.
    Type: Application
    Filed: April 27, 2006
    Publication date: November 2, 2006
    Applicant: TG BIOTECH
    Inventors: Tae-Lin Huh, Hebok Song, Dong-Chan Park, Seung Hwang